- Verve Therapeutics Inc (NASDAQ:VERV) entered into an Amended and Restated Collaboration and License Agreement with Beam Therapeutics Inc (NASDAQ:BEAM), which amended the agreement initially announced in April 2019.
- The original agreement provided Verve with an exclusive, worldwide, sublicensable license under certain of Beam’s base editing, gene editing, and delivery technologies for applications against four liver-mediated cardiovascular disease targets and two undisclosed gene targets.
- Under the amendment, Beam granted Verve a license toward an additional liver-mediated cardiovascular disease target.
- Verve will be responsible for developing and commercializing products targeting such genes, subject to Beam’s opt-in right.
- Following the final dosing of a patient in the Phase 1 trial of a licensed product for such gene, Beam can opt-in to share 35% of development costs, commercializing costs, and profits.
- If Beam does not opt-in, it would be entitled to receive milestones and royalties.
- Verve granted Beam an exclusive license under Verve’s intellectual property, including under Verve’s GalNAc-LNP delivery technology, relating to a preclinical program developed by Verve.
- In addition, the amended agreement grants Beam, on a target-by-target basis, the option to obtain a non-exclusive license to Verve’s GalNAc-LNP delivery technology.
- Beam would owe Verve a fee upon exercise of each option, certain milestones, and low single-digit royalties.
- Price Action: BEAM stock closed at $45.56, and VERV stock closed at $17.59 on Wednesday.
Best Buy’s Q2 Highlights: Earnings Beat, Uneven Sales Environment, Restructuring Initiatives & More
Best Buy Co Inc (NYSE:BBY) reported a second-quarter FY23 sales decline of 12.8% year-on-year to $10.33 billion, beating the consensus of…
